Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
November 2025
in “
Mendeley Data
”
TLDR Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
This study evaluated the efficacy and tolerability of unorthodox weight-stratified dosing regimens of tofacitinib and baricitinib in pediatric patients aged 2–17 years with moderate-to-severe alopecia areata over 24 weeks. Both drugs demonstrated comparable efficacy with no significant differences in primary endpoints and were well-tolerated, showing no serious adverse events. However, the unorthodox twice-daily regimen for baricitinib resulted in lower efficacy for severe cases compared to the standard once-daily regimen, suggesting that guideline-recommended dosing should be prioritized. Unorthodox dosing may be considered in special cases, such as poor tolerability, with therapeutic drug monitoring to ensure effective drug concentrations. Both drugs were deemed safe for short-term use in children, with mild and manageable adverse events.
